**Core Concept**
The de novo synthesis of purines is a crucial metabolic pathway involved in the production of nucleotides, which are essential components of DNA and RNA. This pathway involves a series of enzyme-catalyzed reactions that ultimately lead to the formation of inosine monophosphate (IMP), a key intermediate in purine biosynthesis.

**Why the Correct Answer is Right**
The correct answer is a drug that inhibits the enzyme xanthine oxidase, which is a key enzyme in the de novo synthesis of purines. Xanthine oxidase catalyzes the conversion of hypoxanthine to xanthine and then xanthine to uric acid. By inhibiting this enzyme, the drug reduces the production of uric acid, which is a major contributor to gout and other forms of hyperuricemia. Allopurinol is a well-known xanthine oxidase inhibitor that is commonly used to treat gout and high uric acid levels.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because it does not specifically target the de novo synthesis of purines. Instead, it may affect other metabolic pathways or have different mechanisms of action.
**Option B:** This option is incorrect because it is not a known inhibitor of xanthine oxidase or the de novo synthesis of purines.
**Option C:** This option is incorrect because it may actually increase the production of purines, rather than inhibiting their synthesis.

**Clinical Pearl / High-Yield Fact**
One important clinical consideration when using drugs that inhibit the de novo synthesis of purines is the potential for increased levels of serum creatinine and acute kidney injury, particularly in patients with pre-existing renal impairment.

**Correct Answer: A. Allopurinol**